Brachytherapy pp 261-270 | Cite as

Ocular Plaque Brachytherapy for Uveal Melanoma and Retinoblastoma

  • Naoya Murakami
  • Shigenobu Suzuki
  • Jun Itami


The main topic of this chapter is brachytherapy for ocular tumor. A small dish-shaped applicator is temporarily attached outside of the eyeball where the tumor is located, and after adequate irradiation time, it is removed. Because generally eyeball moves quickly and frequently, it is difficult to irradiate intraocular tumor with external beam technique. When big dose is delivered with adequate margin to compensate the organ motion, it is difficult to preserve visual function. On the other hand, when the applicator is accurately attached to the location of the tumor, the applicator moves together with the eyeball, and it is possible to perform very conformal irradiation. Therefore, ocular plaque brachytherapy is very important for the management of ocular tumors such as uveal melanoma and retinoblastoma.


Plaque brachytherapy Ocular tumors Uveal melanoma Retinoblastoma 


  1. 1.
    Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118:1881–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Hu DN, Yu GP, McCormick SA, et al. Population based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol. 1996;76:784–96.Google Scholar
  3. 3.
    Kaneko A. Incidence of malignant melanoma of the eye in Japan, 1977–1979. Nippon Ganka Gakkai Zasshi. 1982;86:1042–5.PubMedGoogle Scholar
  4. 4.
    Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative ocular melanoma study group report no 26. Arch Ophthalmol. 2005;123:1639–43.CrossRefPubMedGoogle Scholar
  5. 5.
    Mainster MA, Turner PL. Ultraviolet-B phototoxicity and hypothetical photomelanomagenesis: intraocular and crystalline lens photoprotection. Am J Ophthalmol. 2010;149:543–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Shields CL, Furuta M, Berman EL, et al. Choroidal nevus transformation into melanoma:analysis of 2514 consecutive cases. Arch Ophthalmol. 2009;127:981–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report no 28. Arch Ophthalmol. 2006;124:1684–93.CrossRefGoogle Scholar
  8. 8.
    Hawkins BS, Collaborative Ocular Melanoma Study Group. The collaborative ocular melanoma study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol. 2004;138:936–51.CrossRefPubMedGoogle Scholar
  9. 9.
    The Collaborative Ocular Melanoma Study Group. Factors predictive of growth and treatment of small choroidal melanoma:COMS report no. 5. Arch Ophthalmol. 1997;115:1537–44.CrossRefGoogle Scholar
  10. 10.
    The Collaborative Ocular Melanoma Study Group. Accuracy of diagnosis of choroidal melanomas in the collaborative ocular melanoma study. COMS report no. 1. Arch Ophthalmol. 1990;108:1268–73.CrossRefGoogle Scholar
  11. 11.
    Sandinha MT, Farquharson MA. McKay IC et al: Monosomy 3 predicts death but not time until death in choroidal melanoma. Invest Ophthalmol Vis Sci. 2005;46:3497–501.CrossRefPubMedGoogle Scholar
  12. 12.
    Gupta MP, Lane AM, DeAngelis MM, et al. Clinical characteristics of uveal melanoma in patients with germline BAP1 mutations. JAMA Ophthalmol. 2015;133:881–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Plasseraud KM, Cook RW, Tsai T, et al. Clinical performance and management outcomes with the DecisionDx-UM gene expression profile test in a prospective multicenter study. J Oncol. 2016;2016:5325762.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    American Brachytherapy Society–Ophthalmic Oncology Task Force. The American brachytherapy society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13:1–14.CrossRefGoogle Scholar
  15. 15.
    Melia M, Moy CS, Reynolds SM, et al. Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the collaborative ocular melanoma study: COMS QOLS report no. 3. Arch Ophthalmol. 2006;124:226–38.CrossRefPubMedGoogle Scholar
  16. 16.
    Collaborative Ocular Melanoma Study Group. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma, I: visual acuity 3 years following I-125 brachytherapy for choroidal melanoma: COMS report no. 16. Ophthalmology. 2001;108:348–66.CrossRefGoogle Scholar
  17. 17.
    Toyama S, Tsuji H, Mizoguchi N, et al. Long-term results of carbon ion radiation therapy for locally advanced or unfavorably located choroidal melanoma: usefulness of CT-based 2-port orthogonal therapy for reducing the incidence of neovascular glaucoma. Int J Radiat Oncol Biol Phys. 2013;86:270–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Survival rate and risk factors for patients with retinoblastoma in Japan. The Committee for the National Registry of retinoblastoma. Jpn J Ophthalmol. 1992;36:121–31.Google Scholar
  19. 19.
    Shields CL, De Potter P, Himelstein BP, et al. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol. 1996;114:1330–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Shields CL, Mashayekhi A, Au AK, et al. The international classification of retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113:2276–80.CrossRefPubMedGoogle Scholar
  21. 21.
    Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. 8th ed. Hoboken, New Jersey: Wiley-Blackwell; 2017. 978-1-119-26357-9Google Scholar
  22. 22.
    Schueler AO, Fluhs D, Anastassiou G, et al. Beta-ray brachytherapy with 106Ru plaques for retinoblastoma. Int J Radiat Oncol Biol Phys. 2006;64:1212–21.CrossRefGoogle Scholar
  23. 23.
    Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 2010;21:203–12.CrossRefPubMedGoogle Scholar
  24. 24.
    Suzuki S, Yamane T, Mohri M, et al. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011;118:2081–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Murakami N, Suzuki S, Ito Y, et al. 106Ruthenium plaque therapy (RPT) for retinoblastoma. Int J Radiat Oncol Biol Phys. 2012;84:59–65.CrossRefPubMedGoogle Scholar
  26. 26.
    Krema H, Xu W, Payne D, et al. Factors predictive of radiation retinopathy post 125 iodine brachytherapy for uveal melanoma. Can J Ophthalmol. 2011;46:158–63.CrossRefPubMedGoogle Scholar
  27. 27.
    Moore R. Choroidal sarcoma treated by the intraocular insertion of radon seeds. Br J Ophthalmol. 1930;14:145e156.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Naoya Murakami
    • 1
  • Shigenobu Suzuki
    • 2
  • Jun Itami
    • 1
  1. 1.Department of Radiation OncologyNational Cancer Center HospitalTokyoJapan
  2. 2.Department of Ophthalmic OncologyNational Cancer Center HospitalTokyoJapan

Personalised recommendations